DOCSLIB.ORG

1Sustainability Which Creates Value

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
1Sustainability Which Creates Value Sustainability 1 which creates value Our identity Bracco is a privately owned multinational Social responsibility is a Our goal: to be a sustainable and business that operates in the life sciences foundational value of the Bracco financially solid company that sector. A global leader in diagnostic imaging, Group and is at the centre of our places the needs of patients at the Bracco also operates in the medical devices conduct and our business philosophy. very heart of its mission, providing and advanced contrast media administration This has made our family-run high quality products and innovative systems sector, as well as in healthcare services. company increasingly strong and solutions, managing the business in reliable over time. an ethical and fair manner. The Group employs 3,609 people. In 2019, it Diana Bracco|Chairperson Fulvio Renoldi Bracco|CEO reached consolidated turnover of 1.47 billion and CEO of the Bracco Group of Bracco Imaging S.p.A. euros (+13.9% compared to 2018), of which 87% in foreign markets. Through Bracco Imaging, the Group offers an extensive Health services. Analysis, prevention, diagnosis, Vision and innovative product portfolio based on internal dentistry, rehabilitation and personalised treatments. Developing innovative solutions for the prevention research and holds a global leadership position in the Through the Italian Diagnostic Centre (CDI), a Lombard and early identification of illnesses, to improve main diagnostic imaging methods: x-rays, including network of polyclinic healthcare facilities, since 1975 the quality of life. computerised tomography (CT), magnetic resonance, Bracco Group has served more than 18 million patients, ultrasound and nuclear medicine. for a yearly total of more than 200,000 diagnostic procedures, 50 different clinical specialisations and5 Mission Medical devices and administration of contrast million analyses for 500 types of laboratory exams. media. Advanced systems for the administration of The CDI relies on more than 800 specialists. Operating on an international scale thanks to the contrast media in radiology, and software to support direct presence of associates throughout the world the decisions made by radiologists and to monitor and To constantly cutting edge know-how. innovate patient radiation doses. To guarantee ease and control products, services and the expertise of our associates in the generation of images and simplify cardiovascular to offer our customers increasing added value. procedures, offering the patient the highest possible level of treatment. ACIST Medical Systems, a global leader in the market Business areas of systems for the injection of contrast media for Diagnostic imaging. Research, development, cardiology and radiology for diagnostic and intervention production and marketing of contrast media and purposes. Its products see widespread use at a clinical solutions to improve the efficiency of diagnostic level in medical centres, universities and hospital imaging, patient safety and cost effectiveness. facilities in more than 70 countries worldwide. 2019 Sustainability Report 10 Our presence in the world 9 production facilities in many +100 Nations 24 Countries countries all over the world: Bracco Group products are sold in more than 100 nations worldwide and the Group has a presence in 24 countries. Its main market is North America, which has grown by 10%, Germany followed by the Chinese market which Singen recorded the highest growth rate, of 18%. The third reference market is the European, which has seen 5% growth, particularly in Italy, France and Germany. total EUR 1.47 BN sales Europe 518 M 35% of the total Italy Ceriano Laghetto, North America Canada Colleretto Giacosa Japan 665 M Montréal and Torviscosa Saitama 45% of the total Rest of the world United States Switzerland China 287 M Minneapolis Geneva Shanghai 20% of the total 2019 Sustainability Report 11 following primary therapeutic treatment. In the five well as therapeutic purposes, it is called theranostic. Diagnostics and treatment, years after its launch, Axumin® has made a significant While diagnostic imaging has represented 85% of the new treatment paradigms contribution to improving the therapeutic management market in the nuclear medicine area to date, today it of this pathology, quickly becoming a new treatment is expected that theranostics will drive growth in the with the acquisition of Blue Earth standard for patients at international level. The Blue sector and will represent more than 60% of the market Earth Diagnostics pipeline includes innovative agents by the end of 2030. targeting the prostate-specific membrane antigen Our strategy for the future consists of employing In 2019, the Bracco Group completed an extremely (PSMA) in clinical development, like “theranostic” “radio- the important expertise acquired through significant transaction with the acquisition for 450 hybrid” (rh) agents, which have potential applications Blue Earth Diagnostics in the development million dollars of Blue Earth Diagnostics, a company for diagnostic as well as therapeutic purposes in of radiopharmaceuticals, which are capable active in molecular imaging and engaged in research, the treatment of prostate cancer. Fluciclovine F18 of defining new diagnostic and therapeutic development and marketing of radiopharmaceuticals has a broad range of other potential applications in paradigms for various types of cancer, and which for early diagnosis and the optimisation of treatment nuclear cancer imaging in the segment of urology we believe can offer important new options plans for oncological pathologies. With this acquisition, and other specialties, such as neuro-oncology for the for doctors and patients alike. These steps Bracco strengthened its presence in precision medicine identification of cerebral metastases, which Blue Earth are intended to boost our capacity to develop and in personalised diagnostics, increasing its range of Diagnostics is currently testing. highly innovative solutions and products. Founded in innovative solutions capable of handling the 2014, with registered office in Oxford (UK), the company Through the use of diagnostic radiopharmaceuticals, continuously evolving needs of patients and has roughly 100 employees and is one of the major it is possible to understand where the cancer is and spreading the innovation that will shape our players in the sector. Currently, it markets Axumin® its biological behaviour, laying the basis to set up future. (fluciclovine F18), an innovative radiopharmaceutical personalised treatment plans. The property of the approved in the United States and the European radiopharmaceutical to target tumour cells can also Union, to identify through PET (positron emission be exploited for therapeutic purposes. In this case, the tomography) diagnostic exams the presence of a radiopharmaceutical conveys the therapeutic agent recurrence of prostate cancer due to high or increasing to the location of the disease, working to fight the blood levels of the prostate-specific antigen (PSA), cancer. When a drug may be used for diagnostic as 2019 Sustainability Report 12 The long industrial tradition of the Bracco Group has evolved and consolidated over more than ninety years of history 1981 2002 2012 Launch of iopamidol, the first ready- Inauguration of the SPIN production Bracco Imaging strengthens its to-use non-ionic contrast media, in unit in Torviscosa (Udine) presence in Latin America with the Italy and in Germany acquisition of Justesa Imagen do 1927 Brasil, Justesa Argentina, Justesa 2004 Mexico and Silicon Valley Medical 1988 Opening of the Bracco Sine Instruments Elio Bracco founds the Italian Construction of the main Bracco production facility in the high-tech product company E. Merck in Milan Imaging plant in Ceriano Laghetto (MI) industrial area of Shanghai 2014 Loan of 100 million euros from the 1990 2007 EIB for Bracco Imaging investments in 1934 Establishment in Japan of the Bracco - Bracco Imaging opens new laboratories Research & Innovation Cebion, an innovative vitamin C based Eisai joint venture (51% Bracco) and the Bioindustry Park Canavese product is introduced into the market pilot plant close to Ivrea, Turin in Italy and Germany 2016 1994 Bracco and Shanghai Pharmaceuticals Acquisition in the United States of 2008 renew their partnership in China until 1949 Squibb Diagnostics and establishment Acquisition of E-Z-EM, a leading 2037 Construction of the plant in Lambrate, of Bracco Diagnostics Inc. production company in the sector of just outside Milan, which gradually headquartered in Princeton, NJ contrast media and medical devices grows over the years for gastrointestinal radiology 2001 2019 With the acquisition of 1953 Acquisition of Acist Medical Systems, 2010 In the new Lambrate laboratories, the a company based in Minneapolis Start of activities of the Bracco Blue Earth Diagnostics, first internal research centre is founded which is a leader in software- Foundation Bracco Imaging expands its based advanced contrast media personalised diagnostics management and administration portfolio 1975 systems, and discovery of the contrast 2011 Launch of the Italian Diagnostic media based on sulphur hexafluoride Bracco Imaging acquires Swiss Medical Centre, a polyclinical facility, which microbubbles, which allows for Care (now Bracco Injeneering) and the today has a network of 22 facilities in otherwise impossible diagnoses production facility in Singen, Germany Lombardy 2019 Sustainability Report 13 ACIST MEDICAL systems BRACCO
Load more

Recommended publications
  • Not for Immediate Release
    Press Contact: David Pitts Argot Partners 212.600.1902 [email protected] Bracco Imaging Continues its Investment in Delivering Radiological Solutions Growing Breadth of Portfolio, Research, Education and Innovation Initiatives Highlighted at the 2011 RSNA CHICAGO, November 27, 2011 – Bracco Imaging S.p.A. – one of the world’s leading companies in the diagnostic imaging business and part of the Bracco Group – is highlighting the Company’s investment and commitment to imaging agents and radiology solutions across modalities through its growing product portfolio, as well as research, education and innovation, at the 97th Scientific Assembly and Annual Meeting of the Radiological Society of North America (RSNA), which is being held November 27 - December 2, 2011 at Chicago’s McCormick Place, booth #4839. "Bracco remains committed to the diagnostic imaging sector, investing in imaging across modalities, including X-ray, Computed Tomography (CT), Cath Lab, Magnetic Resonance Imaging (MRI), Nuclear Medicine and Ultrasound," according to Fulvio Renoldi Bracco, head of Bracco Imaging, S.p.A. "In a difficult economic climate, where investing in the future is not top of mind, Bracco remains at the forefront. We believe that imaging agents and integrated imaging solutions are critical to support radiologists and other imaging specialists in making an effective diagnosis. Our commitment to providing the market with industry-leading products and solutions, and our partnership with the medical community, therefore remains unchanged." Fulvio Renoldi Bracco concluded: "We perceive this period in the industry, and indeed in the broader markets, as an opportunity to invest and to continue to deliver the best contrast imaging solutions to market.
    [Show full text]
  • PRESS RELEASE Blue Earth Diagnostics Continues to Expand Access to Axumin® (Fluciclovine (18F)) with First Commercial Supply In
    PRESS RELEASE Blue Earth Diagnostics continues to expand access to Axumin® (fluciclovine (18F)) with first commercial supply in Slovakia, Europe Oxford, UK – April 21, 2020 – Blue Earth Diagnostics Ltd, a Bracco company focused on molecular imaging diagnostics, today announced expanded access to Axumin® (fluciclovine (18F)) in Europe. The first commercial delivery of Axumin was made in Slovakia in April 2020. This was possible through the Blue Earth Diagnostics’ distribution partner in Slovakia, MGP, spol. s r. o. Axumin is a PET imaging agent approved in the European Union for use in in men with suspected recurrence of prostate cancer. Axumin is commercially available in Belgium, Luxembourg, Italy, France, Norway, the Czech Republic, The Netherlands, Austria and, now, Slovakia, with further European countries set to follow soon. Prostate cancer is a leading cause of cancer death in men. While most primary prostate cancer can be successfully treated, recurrence occurs in up to one-third of patients. Recurrent disease is typically detected by a rise in PSA levels but often the location and extent of the disease cannot be detected by conventional imaging. Of those who suffer biochemical recurrence, approximately one-third develop metastatic prostate cancer. Axumin was developed to target the increased amino acid transport that occurs in many cancers, including prostate cancer. It is labelled with the radioisotope (18F), enabling it to be visualized in the body with PET imaging. Dr. Jonathan Allis, Chief Executive Officer of Blue Earth Diagnostics
    [Show full text]
  • Art. 31 Gadolinium
    Annex I List of nationally authorised medicinal products 1 Annex IA – medicinal products containing intravenous gadobenic acid, gadobutrol, gadoteric acid, gadoteridol, gadoxetic acid and intra-articular gadopentetic acid and intra-articular gadoteric acid Member State Marketing Invented name INN + Strength Pharmaceutical form Route of EU/EEA authorisation holder administration Austria Bayer Austria GmbH Magnevist Gadopentetate solution for injection intra-aintra-articular use Dimeglumine 1.876mg/Ml Austria Bayer Austria GmbH Dotagraf Gadoteric Acid solution for injection intravenous use 279.32mg/Ml Austria Bayer Austria GmbH Gadovist Gadobutrol solution for injection intravenous use 604.72mg/Ml Austria Bayer Austria GmbH Primovist Gadoxetic Acid, solution for injection intravenous use Disodium 181.43mg/Ml Austria Bracco Imaging S.p.A. Prohance Gadoteridol solution for injection intravenous use 279.3mg/Ml Austria Guerbet Artirem Gadoteric Acid solution for injection intra-articular use 1.397mg/Ml Austria Guerbet Dotarem Gadoteric Acid solution for injection intravenous use 279.32mg/Ml Austria Sanochemia Cyclolux Gadoteric Acid solution for injection intravenous use Pharmazeutika AG 0.5mmol/Ml Austria Bracco Imaging S.p.A. Multihance Gadobenate solution for injection intravenous use Dimeglumine 529mg/Ml Belgium Agfa Healthcare Imaging Dotagita Gadoteric Acid solution for injection intravenous use Agents GmbH 279.32mg/Ml Belgium Bayer SA NV Dotagraph Gadoteric Acid solution for injection intravenous use 279.32mg/Ml 2 Member State Marketing
    [Show full text]
  • Bracco's Lumason
    FOR IMMEDIATE RELEASE Bracco Announces U.S. FDA Approval of 20-Vial Configuration of LUMASON® (sulfur hexafluoride lipid-type A microspheres) for injectable suspension, for intravenous use or intravesical use 20-vial pack provides a green packaging alternative and helps increase storage efficiency Monroe Township, NJ, February 22, 2021 – Bracco Diagnostics Inc., the U.S. subsidiary of Bracco Imaging S.p.A., one of the world’s leading companies in the diagnostic imaging business, announced today that its ultrasound enhancing agent (UEA) LUMASON® (sulfur hexafluoride lipid-type A microspheres) for injectable suspension, for intravenous use or intravesical use, received FDA approval on a new 20-vial pack configuration. This new product configuration provides customers with a green packaging alternative, increased storage space efficiency, and more SKU options. “Bracco is proud to launch this new configuration of LUMASON UEA while still featuring our needleless, air sterile filtration Mini-Spike®, protecting you and your patients1,” said Cosimo De Pinto, Vice President of Sales and Marketing at Bracco Diagnostics Inc. “Whether you are a nurse in the ICU or a sonographer in a high-volume lab where storage is limited and productivity is key, we are committed to providing options that meet our customers’ needs.” LUMASON UEA, known globally as SonoVue®, has a proven safety profile and is the only agent that has multiple indications for adult and pediatric patients.2 This new configuration features twenty vials of LUMASON UEA, each containing 25 mg of lipid-type A lyophilized powder and 60.7 mg sulfur hexafluoride headspace, and a corresponding Mini-Spike for each vial.2 Marketed since 2001 and available in more than 40 countries3, LUMASON UEA is comprised of gas-filled microspheres that reflect the sound waves to enhance the echogenicity of the blood or urine, which results in an improvement in the diagnostic quality of the ultrasound images.4 The agent does not require refrigeration or mechanical agitation.
    [Show full text]
  • Bracco Imaging Collaborates with a Major Academic Medical Center on Improving Patient Care Through New Protocols for Computed Tomography (CT) Imaging
    s contacts: Roberto Cattaneo Bracco Imagin Bracco Imaging Media Relations [email protected] +39-02-21771 FOR IMMEDIATE RELEASE Bracco Imaging collaborates with a major academic medical center on improving patient care through new protocols for Computed Tomography (CT) imaging Milan, Italy, July 31, 2018 - Bracco Imaging S.p.A., a global leader in diagnostic imaging, announced today that has entered into a research collaboration with the Duke University School of Medicine (Durham, North Carolina, U.S.) to improve patient care in Computed Tomography imaging. As part of the collaboration, Bracco will work with Duke on a research program aimed at developing a viable software tool to automatically and predictively estimate iodine enhancement, radiation dose, and image quality for individual patients undergoing a contrast enhanced Computed Tomography imaging procedure. “We look forward to this collaboration in which we will seek to identify new protocols for CT imaging that will hopefully be shown to improve the care of patients,” said Dr. Ehsan Samei, Professor of Radiology and Medical Physics at Duke University School of Medicine, and the lead scientist of the collaboration. “This research will introduce a mechanism by which we hope to demonstrate and validate improvements in image quality and safety in contrast enhanced CT examinations through advanced modeling of contrast perfusion through human body.” “We are proud that Duke, recognized as a world leader in the field of imaging techniques, has agreed to work with Bracco as its key partner for such an important goal”, said Fulvio Renoldi Bracco, Chief Executive Officer at Bracco Imaging. “We strongly believe that Duke’s expertise in advanced imaging applications will contribute to transform patient care by keeping the interest of the patient in the forefront of advanced diagnostic CT imaging.” This collaboration agreement will further accelerate such a pioneering research effort that could evolve into commercial embodiments for advanced contrast enhanced CT imaging technologies.
    [Show full text]
  • Press Contact: Kimberly Gerweck Bracco Diagnostics Inc
    Press contact: Kimberly Gerweck Bracco Diagnostics Inc. Media Relations [email protected] +1 609-524-2777 Bracco Diagnostics Inc. Unveils Contrast Media and Device Offerings That Can Help Build Value and Drive Revenue in Clinical Practice at the 2019 Radiological Society of North America (RSNA) Annual Meeting Monroe Township, NJ, November 25, 2019 – An estimated 600 million medical imaging procedures are performed each year in the United States.1 To demonstrate the company’s commitment to the challenges faced by the healthcare professionals involved in those procedures and the patients they serve, Bracco Diagnostics Inc., the U.S. subsidiary of Bracco Imaging S.p.A., a leading global company in the diagnostic imaging business, reaffirms the company’s vision on addressing the diagnostic imaging needs of today and tomorrow. “We come to this year’s RSNA eager to discuss the science of imaging with our customers and our industry partners,” said Cosimo De Pinto, Vice President of Marketing at Bracco. “To say the next few years are going to be transformational would be an understatement,” says De Pinto. “The balance of providing value-based care while riding the wave of technology and innovation can be daunting for our customers, but we believe we are in a unique position at Bracco to support both endeavors. It’s an exciting time to be in the field of diagnostic imaging.” Bracco will highlight its full scope of offerings and advancements with its diagnostic imaging services and solutions portfolio at the 2019 RSNA Annual Meeting (South Hall Level 3, Booth #3311), including Bracco’s: • Focus on patient care and the power of choice, giving customers the ability to assess each patient’s personal needs and decide upon the best contrast media option for their patients, whether the contrast is for an MRI, X-ray/CT, Ultrasound, or Nuclear Medicine examination.
    [Show full text]
  • FOR IMMEDIATE RELEASE Bracco to Provide a Virtual Experience to Its Customers at the 2020 American Society of Echocardiography
    FOR IMMEDIATE RELEASE Bracco to Provide a Virtual Experience to its Customers at the 2020 American Society of Echocardiography (ASE) Congress Monroe Township, NJ, August 7, 2020– Bracco Diagnostics Inc., the U.S. subsidiary of Bracco Imaging S.p.A., one of the world’s leading companies in the diagnostic imaging business, announced today that it will exhibit an interactive digital experience at the first-ever virtual ASE congress. The Bracco booth will feature its ultrasound enhancing agent (UEA) LUMASON® (sulfur hexafluoride lipid-type A microspheres) for injectable suspension, for intravenous use or intravesical use at the ASE https://ase2020.lumason.com/. The Bracco virtual booth will offer ASE attendees live engagement opportunities with its management team, and gamification of challenging echocardiography cases designed to teach sonographers about wall segments within various apical views. The game is open to all sonographers and echocardiographers at www.GreatSonographer.com. In addition, the company recently launched www.VisuallyDecisive.com, an online teaching portal where customers can book live one-on-one or group appointments with LUMASON Clinical Application Specialists to review cases and learn helpful tips and tricks to obtain optimal images. Sonographers can also play an interactive visual aid, “A Day in the Life of a Sonographer”, where they can experience a wide array of decisions and outcomes to help improve their working day. “The American Society of Echocardiography meeting is an important event Bracco looks forward to attend each year. While this year’s meeting will not allow us to visit with customers in person, it will showcase our remote customer-connect capabilities,” said Cosimo De Pinto, Vice President of Marketing at Bracco Diagnostics Inc.
    [Show full text]
  • Bracco Imaging Acquires Surgvision Expanding Into the Innovative Field of Fluorescence Imaging-Guided Surgery
    Press contacts: Roberto Cattaneo Bracco Imaging Media Relations [email protected] +39-02-21771 Ton van den Hoven SurgVision BV [email protected] +31857600425 FOR IMMEDIATE RELEASE Bracco Imaging acquires SurgVision expanding into the innovative field of fluorescence imaging-guided surgery Milano, Italy, October 18, 2017 – Bracco Imaging S.p.A., a leading global company in diagnostic imaging, today announced the acquisition of SurgVision, a high-tech start-up focused on developing a real-time Fluorescence Image Guided Surgery platform combining targeted imaging agent and a device for efficient tumors visualization during oncology surgical procedures. As surgery remains the primary curative option for most solid cancers, a predominant challenge for surgeons during these procedures has been the limitations of visual inspection and digital palpation to distinguish tumors from healthy tissue. Fluorescence Image Guided Surgery represents an innovative intra-operative optical technique aimed at assisting surgeons in distinguishing tumors from surrounding tissue, using a combined infrared camera and contrast agent approach. In this context, SurgVision’s innovative targeting solution is expected to provide significant improvements versus competing modalities and products, due to the extremely advanced features of its optical camera and the very sensitive targeting performance of its new imaging agent. “With the acquisition of SurgVision, one of the most advanced companies in a very promising field, we intend to address a relevant, unmet medical need for oncology patients who have to undergo tumor removal surgery” said Fulvio Renoldi Bracco, Chief Executive Officer at Bracco Imaging. “SurgVision platform expands our imaging solutions for healthcare professionals in oncology and reinforces our long-lasting commitment to patient care” he concluded.
    [Show full text]
  • Bracco Imaging Reinforces Its Commitment to Innovation in Ultrasound for the Development of a New Personalized Gene Therapy
    Press contacts: Roberto Cattaneo Bracco Imaging Media Relations [email protected] +39-02-21771 FOR IMMEDIATE RELEASE Bracco Imaging reinforces its commitment to innovation in ultrasound for the development of a new personalized gene therapy Milan, Italy, January 23, 2018 - Bracco Imaging S.p.A., a global leader in diagnostic imaging, announced today that it has initiated new experimental activities in its R&D Center in Geneva, Switzerland, to explore a new application for gas-filled microbubbles in the development of personalized gene therapy for treatment of chronic dysfunctional diseases related to lipid metabolism. Microbubbles have already revolutionized medical imaging in the field of Contrast Enhanced Ultrasound (CEUS) - a high-sensitivity, non-invasive, real-time, cost-effective and radiation-free modality that improves the visualization and assessment of cardiac cavities, large vessels and tissue vascularity. As an established and robust tool for diagnostic imaging, microbubbles are now also considered a platform for therapeutic drug or gene delivery. “Today’s kick-off of new research activities provides an additional opportunity to exploit the microbubble platform and create an innovative therapeutic approach to addressing unmet medical needs,” said Thierry Bettinger, PhD, Research Department Director at Bracco Suisse SA. “We consider the personalized gene therapy under evaluation as an opportunity to expand the use of the microbubble platform. We are looking for a large number of biomedical applications, and are confident that our technology can be used to address a wide range of healthcare challenges.” This research project is the result of an agreement that Bracco has recently signed with SonoGene LCC, an innovative start-up company focused on the development of novel platforms for therapeutic delivery of genes and pharmaceuticals using ultrasound-triggered, non-viral microbubble delivery systems.
    [Show full text]
  • List Item Gadolinium Article-31 Referral – Annex I (PDF/305.84
    Annex I List of nationally authorised medicinal products 1 Annex IA – medicinal products containing intravenous gadobenic acid, gadobutrol, gadoteric acid, gadoteridol, gadoxetic acid and intra-articular gadopentetic acid and intra-articular gadoteric acid Member State Marketing Invented name INN + Strength Pharmaceutical form Route of EU/EEA authorisation holder administration Austria Bayer Austria GmbH Magnevist Gadopentetate solution for injection intra-aintra-articular use Dimeglumine 1.876mg/Ml Austria Bayer Austria GmbH Dotagraf Gadoteric Acid solution for injection intravenous use 279.32mg/Ml Austria Bayer Austria GmbH Gadovist Gadobutrol solution for injection intravenous use 604.72mg/Ml Austria Bayer Austria GmbH Primovist Gadoxetic Acid, solution for injection intravenous use Disodium 181.43mg/Ml Austria Bracco Imaging S.p.A. Prohance Gadoteridol solution for injection intravenous use 279.3mg/Ml Austria Guerbet Artirem Gadoteric Acid solution for injection intra-articular use 1.397mg/Ml Austria Guerbet Dotarem Gadoteric Acid solution for injection intravenous use 279.32mg/Ml Austria Sanochemia Cyclolux Gadoteric Acid solution for injection intravenous use Pharmazeutika AG 0.5mmol/Ml Austria Bracco Imaging S.p.A. Multihance Gadobenate solution for injection intravenous use Dimeglumine 529mg/Ml Belgium Agfa Healthcare Imaging Dotagita Gadoteric Acid solution for injection intravenous use Agents GmbH 279.32mg/Ml Belgium Bayer SA NV Dotagraph Gadoteric Acid solution for injection intravenous use 279.32mg/Ml 2 Member State Marketing
    [Show full text]
  • 208844Orig1s000
    CENTER FOR DRUG EVALUATION AND RESEARCH APPLICATION NUMBER: 208844Orig1s000 MEDICAL REVIEW(S) CLINICAL REVIEW Application Type New Drug Application, 505(b)(2) Application Number(s) NDA 208036 Priority or Standard Standard Submit Date(s) December 11, 2014 Received Date(s) December 11, 2014, September 14, 2015 PDUFA Goal Date January 11, 2016 Reviewer Name(s) Brenda Ye, M.D. Review Completion Date November 16, 2015 Established Name Barium sulfate powder for suspension (Proposed) Trade Name E-Z-HD Therapeutic Class Oral contrast agent Applicant Bracco Diagnostics Inc. Formulation(s) 98% w/w powder for suspension Dosing Regimen Volume administered varies based on clinical condition, and anatomic characteristics. Indication(s) Double contrast examination of the esophagus, stomach and duodenum under fluoroscopic guidance. Reference ID: 3847706 Intended Population(s) Adults Reference ID: 3847706 Clinical Review Brenda Ye, M.D. NDA # 208036 E-Z-HD Barium Sulfate Table of Contents 1 RECOMMENDATIONS/RISK BENEFIT ASSESSMENT..................................................................................5 1.1 Recommendation on Regulatory Action..............................................................................................................5 1.2 Risk Benefit Assessment......................................................................................................................................5 1.3 Recommendations for Post-market Risk Management Activities .......................................................................6
    [Show full text]
  • The Cost of Developing Imaging Agents for Routine Clinical Use
    ORIGINAL ARTICLE The Cost of Developing Imaging Agents for Routine Clinical Use Adrian D. Nunn, PhD the therapeutic agents, although increased funds are being Abstract: The objective of this study was to estimate the financial spent, this has not led to increased submissions or approvals cost of developing new imaging agents for clinical use and to of imaging agents. The increased funds expended on devel- discuss the effects of these costs on the future clinical imaging agent oping imaging agents have been channeled in part to pay for environment. Publicly available financial data from the annual the increased cost of bringing an NCE to the market. The reports of major companies developing and selling imaging agents development costs for diagnostic imaging agents have in- were examined and the data used to develop cost estimates. These creased in the same way as have those for therapeutic drugs. estimates were compared with the in-depth data and analyses avail- However, although the development costs of therapeutic able for the development costs of therapeutic drugs. The cost of drugs are relatively well known, although still controversial, developing a drug for diagnostic imaging to commercialization is in no such data are generally available for imaging agents. The the $100 to $200 million range, whereas a blockbuster imaging drug therapeutic pharmaceutical industry consists of many compa- has current sales of $200 to $400 million. Most of these blockbuster nies that has allowed the collection, analysis, and publication imaging agents have been on the market for some time. The majority of primary confidential information whilst maintaining the provide morphologic images with general indications in a slowly confidentiality of the details.1 In contrast, there are a limited changing section of the market.
    [Show full text]